Market research
7EYA.F EyeGate Pharmaceuticals, Inc
F EUR Healthcare
Latest close
As of 04 Dec 2024
Test a moving-average rule with historical data.
Market facts
- Market cap
- 21M
- P/E ratio
- Not available
- Analyst target
- 10.25
- Dividend yield
- Not available
- Beta
- 1.12
Profile
Instrument facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 21M
- P/E ratio
- Not available
- Analyst target
- 10.25
- Dividend yield
- Not available
- Beta
- 1.12
About
About EyeGate Pharmaceuticals, Inc
Kiora Pharmaceuticals, Inc., an ophthalmic specialty pharmaceutical company, develops therapies for the treatment of eye diseases in the United States. Its pipeline includes KIO-101, a small molecule DHODH inhibitor that treats immunologic eye diseases; KIO-201, an eye drop that enhances ocular wound healing and protects the ocular surface; and KIO-301, a small molecule that has the potential to restore vision in patients with inherited or age related retinal degeneration. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is based in Salt Lake City, Utah.
Research context
EyeGate Pharmaceuticals, Inc appears in PyInvesting’s Frankfurt Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the 7EYA.F discussion.
5 years, 7 months ago
EyeGate Pharmaceuticals, Inc is currently in a long term downtrend where the price is trading 24.3% below its 200 day moving average.
From a valuation standpoint, the stock is 43.0% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 1877.8.
EyeGate Pharmaceuticals, Inc's total revenue rose by inf% to $12K since the same quarter in the previous year.
Its net income has increased by 10.6% to $-2M since the same quarter in the previous year.
Finally, its free cash flow grew by 33.1% to $-2M since the same quarter in the previous year.
Based on the above factors, EyeGate Pharmaceuticals, Inc gets an overall score of 3/5.